Biden Administration To Stop Purchasing COVID-19 Solutions By End Of 2022
As the U.S. plans to get out of the crisis phase, the Biden administration said it would stop buying…
Retail Earnings Underway With Target, Walmart Results: Which Of These 5 Retail Stocks Offer Best Dividends?
As we progress through the second quarter earnings season, many top retailers are reporting earnings this week.
AbbVie Calls Off Early-Stage Trial For I-Mab’s CD47-Targeted Blood Cancer Candidate
I-Mab (NASDAQ:IMAB) disclosed in an SEC filing that AbbVie Inc (NYSE:ABBV) would discontinue the global Phase 1b study of lemzoparlimab combination therapy with…
AstraZeneca Slaps Lawsuit Against Former Employee As He Moves To Close Rival: Report
AstraZeneca Plc (NASDAQ:AZN) has filed suit against former VP and head of investor relations Chris Sheldon as he prepares…
GSK’s Rare Blood Cancer Candidate Goes Under FDA Review
The FDA has accepted GSK plc’s (NYSE:GSK) marketing application for momelotinib, a potential new medicine with a proposed differentiated mechanism of…
Roche’s Polivy Combo Regime Under FDA Review For Type Of Blood Cancer
Roche Holdings AG (OTC:RHHBY) announced that the FDA accepted its supplemental marketing application for Polivy. Polivy is being developed by Roche…
These 3 High-Yielding Defense Stocks Will Protect Your Portfolio As Geopolitical Tensions Worsen
As the Ukraine-Russia war progresses, and tensions between China and the U.S. escalate on the heels of House Speaker Nancy Pelosi's visit to Taiwan, investors may wonder how they can hedge against these geopolitical issues.
One way is to purchase these dividend-paying defense stocks:
Merck Bets $250M On Next-Gen Approach To mRNA For Infectious Diseases, Cancer
Merck Co & Inc (NYSE:MRK) and Orna Therapeutics announced a collaboration agreement to discover, develop, and commercialize multiple programs, including vaccines and therapeutics…
After Surprise Overall Survival Data In Metastatic Breast Cancer, Gilead Takes Complete Rights To Trodelvy
Everest Medicines will transfer all development and commercialization rights of Trodelvy (sacituzumab govitecan) to Gilead Sciences Inc (NASDAQ:GILD) in Greater China, South…
Your Pet Or Car? When Times Got Rough, Consumers Made A Tough Choice This Summer
Freshpet Inc’s (NASDAQ: FRPT) second-quarter earnings report offered great insight into the current macroeconomic trends currently affecting the pockets of Americans.